Please assess the completion status of the following clinical trial:

Trial Title: Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-II congestive heart failure~* History of Stage C-D heart failure with EF ≤ 40% during the course of the disease~* Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant)~* Age \> 18 yrs~Exclusion Criteria:~* Cardiomyopathy due to one of the following:~  * Ischemic heart disease~ * Primary valvular lesion~ * Hypertrophic cardiomyopathy~* Cardiac resynchronization within the last 3 months~* Transaminase values \> 2.5 x upper limit of normal or history of liver disease~* Diagnosis of diabetes mellitus by:~  * Diabetes previously diagnosed per patient history~ * 2 or more fasting glucose values \> 125 mg/dl~* Current NYHA class III or IV heart failure~* Serum creatinine \> 1.6 mg/dl~* History of heart transplantation~* Pregnancy or active breast feeding~* Hospitalization for decompensated heart failure within 30 days prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).